Related Experiment Video
Updated: Aug 19, 2026

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
Published on: October 21, 2017
[Disturbances of calcium-PTH-vitamin D axis in chronic liver diseases]
Rodrigo O Moreira1, Mônica P C Duarte, Maria Lucia F Farias
1Serviço de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. rom_br@yahoo.com
Abstract:
Disturbances in Calcium-PTH-Vitamin D axis are frequently associated with chronic liver diseases (CLD). In patients with CLD, a trend toward decreased serum calcium and vitamin D has already been demonstrated with compensatory increases in PTH levels. Even though reduced vitamin D hydroxylation has been considered the most important mechanism for these alterations, recent studies demonstrates an adequate production of 25(OH) Vitamin D even in end-stage liver disease. Therefore, other factors (i.e. inadequate diet, reduced exposure to sun light) would be responsible for the disturbances in calcium-PTH-vitamin D axis. Furthermore, antiviral drugs (such as ribavirin for hepatitis C) and glucocorticoids (cystic fibrosis) may also contribute to the worsening of these disturbances. On the other hand, osteoporosis, but not osteomalacia or secondary hyperparathyroidism, seems to be the main alteration in CLD. Thus, the clinical relevance of calcium-PTH-vitamin D disturbances in hepatic osteodystrophy is still under discussion.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Skeleton and Calcium Homeostasis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow